{"disease":{"id":"secondary-aml","name":"secondary aml"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04230239","title":"Clinical Trial to Assess the Efficacy and Toxicity of Induction and Consolidation With CPX-351 for Patients Aged 60 to 75 Years With Secondary or High-risk Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":59,"lead_sponsor_name":"PETHEMA Foundation","has_results":false},{"nct_id":"NCT00531232","title":"A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":true},{"nct_id":"NCT02533115","title":"EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Jazz Pharmaceuticals","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}